The present invention relates to a method for irradiating a population of mammalian cells comprising at least one target mammalian cell with electron beams and/or X-rays, characterized in that: (i) a composition comprising a population of mammalian cells is irradiated in vitro with electron beams and/or X-rays, the population of mammalian cells containing at least one target mammalian cell and the dose rate being within the range from 5 Gy/sec to 10.sup.7 Gy/sec, and (ii) optionally viable target mammalian cells are isolated or enriched from the population of mammalian cells, and to agents obtainable thereby and to uses thereof.

Disclosed herein is a formulation comprising an extracellular vesicle (EV), and a therapeutic active agent induced or embedded in the EV. According to preferred embodiments of the present disclosure, the EV is isolated from umbilical cord mesenchymal stem cells, and the active agent may be a growth factor, an immune-modulating agent, a small molecule, an siRNA, cDNA or a plant ingredient; for example, curcumin. Also disclosed herein are methods for producing the present formulation, and uses of the present formulation in the treatment of various diseases.

The present invention relates to compositions and methods for destroying target cells in a patient using photodynamic therapy. In particular, the present invention provides a photosensitizing agent based on a small molecular weight (<50 kDa) protein or peptide or a small molecule that is conjugated to a phthalocyanine dye, such as IRDye 700DX.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

Infectious diseases can be transmitted to humans, or between humans and animals, by airborne viruses and bacteria, known as infectious aerosols. Current protective measures that individuals can take to avoid inhaling such aerosols are either marginally effective (personal face masks) or impractical (self-contained breathing apparatuses). Building ventilation systems employing high-efficiency filters to prevent distribution of such aerosols suffer from high energy costs and high filter replacement costs. The development of conventional, intramuscularly administered vaccines takes months or years to produce enough doses to protect a population from a rapidly spreading infectious disease. Airborne viruses and bacteria have been shown to be completely inactivated when exposed to non-thermal plasmas. Results indicate the potential for sub-lethal exposures of airborne pathogens could render them unable to spark an infection in a host, but still retain the necessary surface proteins to cause an immune response in the host.

A plasma activated ophthalmic solution generating device operable to generate a therapeutic ophthalmic solution for curing epidemic keratoconjunctivitis includes a plasma generating electrode operable to generate a plasma activated ophthalmic solution for epidemic keratoconjunctivitis, wherein the plasma generating electrode is arranged surrounding an insert space where a unit dose ophthalmic eyedrop container with a container body, which seals a certain solution in a sterile state, is inserted; a power supply unit; and a high voltage generating unit, which is connected to the power supply unit, operable to be supplied with power source from the power supply unit and to apply high voltage electric current to the plasma generating electrode. This configuration makes it possible to provide a novel and effective therapeutic ophthalmic solution for epidemic keratoconjunctivitis (EKC).

Embodiments are described for treating a fluid, e.g., a biological fluid. The embodiments may include systems, apparatuses, and methods. Embodiments may provide for a flow cell, with a plurality of manipulation elements, through which a fluid is flowed. The fluid may be treated (e.g., exposed to energy) as it moves through the flow cell. In embodiments, the flow cell may be used to inactivate pathogens in the fluid.

Immunogenic compositions and systems are disclosed, as well as methods for producing the immunogenic compositions. Compositions, systems, and methods of reducing viability of cancer cells and treating cancer, as well as methods of reducing volume of a tumor and/or preventing an increase in volume of a tumor present in a body of a living subject, are also disclosed. The systems and methods involve application of an alternating electric field to cancer cell(s) (before or after isolation from a targeted portion of a subject), and irradiation of the isolated and treated cancer cell(s). The methods may further include administration of the irradiated, treated cancer cells back to the subject from which the cancer cell(s) were isolated, and/or application of an alternating electric field to the subject. The immunogenic compositions comprise populations of isolated, apoptotic cancer cells.

Immunogenic compositions and systems are disclosed, as well as methods for producing the immunogenic compositions. Compositions, systems, and methods of reducing viability of cancer cells and treating cancer, as well as methods of reducing volume of a tumor and/or preventing an increase in volume of a tumor present in a body of a living subject, are also disclosed. The systems and methods involve application of an alternating electric field to cancer cell(s) (before or after isolation from a targeted portion of a subject), and irradiation of the isolated and treated cancer cell(s). The methods may further include administration of the irradiated, treated cancer cells back to the subject from which the cancer cell(s) were isolated, and/or application of an alternating electric field to the subject. The immunogenic compositions comprise populations of isolated, apoptotic cancer cells.